Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates CEL-SCI partnered with the University of Georgia’s Center for Vaccines and Immunology to develop immunotherapy against Covid-19 infection using its LEAPS peptide approach.
The company began efforts to develop an immunotherapy for the potential treatment of Covid-19 earlier this month. The partners will conduct pre-clinical studies based on findings from prior testing of LEAPS immunotherapy with the National Institutes for Allergies and Infectious Diseases (NIAID) against H1N1 respiratory virus.
Based on the previous studies, the immunotherapy should reduce or prevent the progression of the novel coronavirus infection, while also expected to block tissue